Author

Benjamin Kasenda

University Hospital of BaselORCID 0000-0003-0110-8585Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:proteomics· 1

Frequent Co-Authors

Heinz Philipp LaubliiD· 3 shared Mascha BinderiD· 3 shared Anne EugsteriD· 2 shared Christoph SchultheißiD· 2 shared Claudia FischeriD· 2 shared Jakob Robert PasswegiD· 2 shared Matthias PeippiD· 2 shared Alessia G LineriD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Heinz Philipp LaubliORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 20, 2026

Targeting poorly differentiated thyroid cancer with bispecific antibodies and CAR T cells from the human anti-TSHR autoantibody repertoire

Claudia Fischer, Anne Eugster, Brenda Besemer…·Mascha Binder

This paper explores using anti-TSHR autoantibodies to create bispecific antibodies and CAR T cells for treating poorly differentiated thyroid cancer, showing potent in vitro and in vivo activity.

DOI 10.64898/2026.10.19.760040

humanexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 23, 2025

Longitudinal profiling of tumor-reactive T cells during TIL therapy in metastatic melanoma

Michael T. Sandholzer, Clara Serger, Alessia G Liner…·Heinz Philipp Laubli

This study profiles tumor-reactive T cell dynamics during TIL therapy in metastatic melanoma, identifying factors associated with response and resistance.

DOI 10.1101/2025.09.23.678066

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologyHaematologicaPeer-reviewedSep 11, 2025

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

Claudia Fischer, Shih‐Shih Chen, Johanna Nimmerfroh…·Mascha Binder

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

1 citation

humanproteomics

𝕏 PostBluesky